SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced a collaboration with Urology Centers of
Alabama (UCA) in the Cchek™ early
prostate cancer detection study. UCA will provide patient
samples in Anixa's ongoing study, including support of clinical
validation of Anixa's Cchek™ Prostate Cancer Confirmation
test.
UCA is one of several sites across the U.S. participating in
this study. Dr. Charles Edward Bugg,
Jr. will serve as the Principal Investigator at UCA.
Amit Kumar, Ph.D., Chief
Executive Officer of Anixa, stated, "We are pleased to have another
highly regarded urology practice join our team of collaboration
partners. We look forward to UCA's participation as we
continue the clinical validation phase of the Cchek™ Prostate
Cancer Confirmation test in preparation for commercial launch later
this year."
About Cchek™
Cchek™ is an early cancer detection
technology, that measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method that offers improved
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
Urology Centers of Alabama
For over 60 years, Urology
Centers of Alabama has been
committed to providing the highest quality medical services in a
compassionate and caring environment. With 24 skilled
urologists, two urogynecologists, two radiation oncologist, one
medical oncologist, one pathologist, a team of physicians'
assistants and nurse practitioners and over 160 employees, the
practice has earned a well deserved reputation for excellence.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-collaboration-with-urology-centers-of-alabama-on-cchek-prostate-cancer-study-300963557.html
SOURCE Anixa Biosciences, Inc.